Monoclonal Antibodies
Omalizumab for Food Allergy
This trial aims to investigate if individuals with food allergies have skin barrier issues that can be improved with a medication called omalizumab. They will compare the skin barrier of food allergic participants before and
Popular Filters
Trials for Peanut Allergy Patients
Immunotherapy
Oral Immunotherapy for Peanut Allergy
This trial studies how gradually eating small amounts of peanut can help people with peanut allergies reduce their allergic reactions. It focuses on individuals aged 6 months to 65 years and aims to improve their quality of life and predict who will benefit most from this treatment. A specific preparation of peanut allergen was approved for younger patients with a peanut allergy.
Microbiome Modulator
VE416 for Peanut Allergy
This trial tests VE416, a capsule with friendly bacteria, combined with an antibiotic and peanut flour, to help people with peanut allergies. The bacteria activate in the intestines and may help prevent allergic reactions. The goal is to see if this combination is safe and effective.
Behavioural Intervention
iREACH CDS Tool for Preventing Peanut Allergy
This trial will assess whether an electronic health record-based tool can help doctors better adhere to guidelines around preventing peanut allergies, with the goal of reducing the incidence of peanut allergies.
Biologics for Food Allergies
This trial tests omalizumab and dupilumab with oral immunotherapy in people aged 4 to 55 who have multiple food allergies, including peanut. The treatments aim to reduce allergic reactions and help the body build tolerance to allergens. Omalizumab has shown potential in speeding up the process and making it safer.
Trials With No Placebo
Behavioral Intervention
Food Allergy Mastery Program for Food Allergies
This trial will examine a new program to help teens with food allergies learn how to manage their condition, with education, problem-solving, communication, and peer support.
Immunotherapy
Oral Immunotherapy for Peanut Allergy
This trial studies how gradually eating small amounts of peanut can help people with peanut allergies reduce their allergic reactions. It focuses on individuals aged 6 months to 65 years and aims to improve their quality of life and predict who will benefit most from this treatment. A specific preparation of peanut allergen was approved for younger patients with a peanut allergy.
Immunotherapy
Low-Dose Multi-Oral Immunotherapy for Food Allergies
This trial tests if giving nut-allergic children very small amounts of multiple nuts can help them tolerate these nuts without allergic reactions. The goal is to make their immune system get used to the nuts over time.
Frequently Asked Questions
Introduction to food allergy
What are the top hospitals conducting food allergy research?
When it comes to advancing our understanding and treatment of food allergies, several leading hospitals are at the forefront of clinical trials. In New york City, the Icahn School of Medicine at Mount Sinai is making significant strides with three ongoing food allergy trials. While they have only recorded one trial in this field thus far, their commitment to research and innovation is evident. Boston's Massachusetts General Hospital also plays a crucial role in this arena, currently conducting two active food allergy trials. Although they do not have any previous recorded trials specifically focused on food allergies, their expertise and resources make them an important contributor to the field.
Heading down south to Washington D.C., Childrens' National Hospital is dedicated to improving our understanding of food allergies through one ongoing clinical trial. Similarly, Novartis Investigative Site in Ypsilanti and San Jose are each engaged in advancing knowledge about food allergies with one active trial each.
These institutions across different locations signify the collective effort being made towards unraveling the complexities surrounding food allergies—a condition that affects millions worldwide. By conducting these essential clinical trials, researchers aim to find novel treatments and therapies that can alleviate symptoms or even prevent allergic reactions altogether. The dedication shown by these hospitals underscores not just their commitment but also their profound compassion for those living with this challenging medical condition—and gives hope for a future where individuals can enjoy meals without fear or restriction
Which are the best cities for food allergy clinical trials?
New york, New York; Boston, Massachusetts; and Baltimore, Maryland emerge as the most promising cities for food allergy clinical trials. These locations offer a range of ongoing studies focused on various treatments such as Ligelizumab 120 mg, Abrocitinib 100mg, peanut oral immunotherapy, and more. With five active trials in New York City, four in Boston, and three in Baltimore—all investigating innovative approaches to managing food allergies—these cities provide individuals with opportunities to participate in cutting-edge research that may pave the way for improved treatment options and enhanced quality of life.
Which are the top treatments for food allergy being explored in clinical trials?
When it comes to the exploration of treatments for food allergy in clinical trials, there are a few standout contenders. One such treatment being investigated is oral immunotherapy, which involves gradually introducing small amounts of the allergen into the patient's diet to build tolerance. Another promising avenue is sublingual immunotherapy, where drops or tablets containing extracts of the allergen are placed under the tongue. These approaches aim to desensitize individuals and reduce allergic reactions over time. Exciting advancements are also being made with biologics, specifically anti-IgE antibodies that target and neutralize allergic responses. With ongoing research and development in these areas, hope continues to grow for effective solutions to combat food allergies.
What are the most recent clinical trials for food allergy?
Significant progress is being made in the field of food allergy research, with recent clinical trials offering promising insights into potential treatments. One such trial investigated the use of antibiotics combined with microbiota-targeted therapy (MTT) in managing food allergies. The results from this Phase 2 study demonstrated encouraging outcomes for patients. Additionally, a Phase 3 trial evaluated ligelizumab at a dosage of 120 mg as a treatment option for food allergy sufferers. Another noteworthy trial explored abrocitinib at a strength of 100mg and its efficacy in addressing food allergies during its Phase 1 stage. Finally, two trials—ADP101 and prebiotic—have shown positive developments during their respective Phase 1 and Phase 2 stages. These exciting clinical trials offer hope to those living with food allergies, indicating advancements in understanding and potentially mitigating allergic responses to certain foods.
What food allergy clinical trials were recently completed?
A recently completed clinical trial focused on food allergies highlights the ongoing efforts to advance treatments in this field. In December 2021, Johns Hopkins University successfully wrapped up a trial investigating Acalabrutinib's potential impact on food allergy management. This study constitutes an important step forward in our understanding of how to address and potentially alleviate the challenges faced by individuals with food allergies. The findings of this trial contribute valuable insights that may pave the way for improved therapies and enhanced quality of life for those affected by these conditions.